FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate toSevere Opioid Use Disorder
May 23, 2023FDA Approves Paxlovid (nirmatrelvir tablets and ritonavir tablets) for Adult Patients at High Risk ofProgression to Severe COVID-19
May 25, 2023May 24, 2023 - Celltrion USA has announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma®(adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
Yuflyma is Celltrion’s fifth biosimilar and second anti-TNF biosimilar approved for use in the United States. Yuflyma will offer patients pre-filled syringe and autoinjector administration options to meet different preferences and needs.